September 16, 2021
Article
Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.
Dr. Jason Liu and his colleagues hoped to assess the use of maintenance durvalumab based on patient and physician characteristics among individuals with stage 3 NSCLC in the United States.
Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
September 15, 2021
Pharmacy health-system managers should understand the key components of the drug quality and security act.
Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.
The regimen with chemotherapy continues to show longer rates at 9 months compared with 4.9 months for chemotherapy and the placebo.
In the MAGNOLIA trial, the median duration of response was not reached at the median follow-up time of 8.3 months, with 85% of responders still in remission at 12 months.
Among patients treated with the combination of nivolumab and ipilimumab, 23% were alive at 3 years, compared to 15% of patients treated with chemotherapy.
Cabozantinib (Cabometyx) was approved in 2016 for patients who have advanced renal cell carcinoma and who received prior anti-angiogenic therapy.
